Research topic
15 articles tagged “Dividends”
Open the Dividends research hub →
P&G's fiscal Q1 organic sales rose 4% on volume and mix with little price, but core gross margin fell 150 basis points and the FY27 cost and currency headwind rose to $0.79 a share.
UPS revenue rose 6.7% in Q3 but adjusted operating margin fell to 9.0% from 10.0%, U.S. volume fell 3.3%, and Supply Chain Solutions adjusted profit fell 49% on 18% revenue growth.
Visa beat estimates and raised its dividend 16%, but client incentives grew 21%, costs matched revenue growth, and free cash flow rose 2% on 17% profit growth.
IBM beat on Q3 revenue and raised its cash flow outlook, but about half of software growth was acquired and most of the nine-month cash flow gain is working capital.
Realty Income is deploying capital at a 235bps spread over its 4.75% borrowing cost — the widest in five years — while 671 consecutive monthly dividends, AFFO growing 6.6% YoY, and a private capital platform with Apollo and GIC are being completely ignored by the ‘rate-sensitive REIT’ label.
General Mills’ Q4 FY2026 adjusted EPS beat consensus by 15.9% and the company launched a $3B cumulative cost savings program — both buried under a $2.1B non-cash goodwill impairment. The real business is inflecting positively; the GAAP headline is accounting noise.
Verizon posted its first positive Q1 postpaid adds since 2013. Frontier fiber convergence yields 30% lower churn on bundled customers, backed by a 6.1% yield and 21 consecutive annual dividend raises.
Kraft Heinz's 7.1% dividend yield is pricing in a cut that 1.9x free cash flow coverage doesn't support. New CEO Steve Cahillane's $600M investment cycle follows the same playbook that worked at Kellogg's.
AT&T's 45% fiber-to-wireless attach rate and a quantified $6.5-8.0B OBBBA tax tailwind are accelerating deleveraging — while the market still prices T as a debt-overhang story.
Dow's Q1 beat and Q2 guidance raise to $2.2B operating earnings signal the chemicals cycle has bottomed — while European plant rationalization permanently removes supply the Street's oversupply thesis hasn't priced in.
Conagra's 11% dividend yield is pricing in a B&G Foods-style halving — but Conagra runs at 3.8x leverage versus B&G's 6-8x, and Q3 organic sales just returned to growth led by Frozen and Snacks.
Pfizer's April 2026 patent settlements quietly pushed the Vyndaqel franchise cliff from 2029 to mid-2031 — while a 39%-growing Padcev franchise and a hidden obesity option in Metsera remain priced near zero. The market hasn't caught up.
Altria has re-rated 27% to ~$72, yet still trades at 13x against a 19x historical average while consensus prices three demonstrably wrong calls: a "volume cliff" offset by relentless pricing power, a smoke-free option marked near zero after NJOY, and a ~$9B ABI stake buried by single-multiple math. Forensic case: BUY, $82 in 12 months, $95+ long-term.
BMY trades at 9.3x P/E and a 4.5% yield while three forensic mispricings sit in plain sight: the Eliquis IRA cliff that didn't happen, a growth/legacy crossover already cleared in 2025, and a $14B Cobenfy option the Street is valuing at zero. Rating: BUY. 12-month target $78, multi-year intrinsic $95+.
Hershey trades at 19x forward earnings versus a 10-year median of 26x, while consensus prices in three demonstrably wrong assumptions about cocoa, GLP-1s, and Salty Snacks. The forensic case points to $235 in 12 months and $275+ longer term. Option 2 — Contrarian hook The market thinks GLP-1s will hurt chocolate demand — peer-reviewed Cornell data shows the opposite. Combined with the cocoa hedge lag and an unmodeled Salty Snacks asset, Hershey's mispricing is measurable, falsifiable, and worth 25%+ upside.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
